AngioSoma Launches E-Commerce Website
HOUSTON, TX, April 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN), a leading developer of dietary supplements and biotechnology research and development company, is pleased to announce the launch of its long awaited e-commerce website: .
Our website will emphasize our workout amplifier, StemStrength Deluxe AM and PM for men and women. The website also offers beauty products including Anti-Aging Crème, Eye Serum and Anti-Wrinkle Serum.
“We are excited about our new website,” said Alex Blankenship, President of AngioSoma. “The greater visibility for offering our supplements for sale to the public is a substantial step forward.”
AngioSoma is moving forward with the pending combination with Diabetes Relief that will complement the treatment of peripheral neuropathy along with our patented drug, Liprostin. The Company is continuing to explore opportunities to move forward with the final clinical trials to receive FDA approval.
Lower extremity peripheral artery disease is the third leading cause of death from hardening of the arteries to the heart (atherosclerotic cardiovascular morbidity), following coronary artery disease and stroke.
More than 20 million people in the United States have been estimated to have some form of peripheral neuropathy, but this figure may be significantly higher—not all people with symptoms of neuropathy are tested for the disease and tests currently don’t look for all forms of neuropathy. Neuropathy is often misdiagnosed due to its complex array of symptoms.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a new e-commerce website to market a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
CONTACT
AngioSoma, Inc.
Alex Blankenship
(832) 781-8521
